852 Results

People

  1. Pasternak
    Pasternak
  2. Schwartz
    Schwartz
  3. Marks
    Marks
  4. Rosen
    Rosen
  5. Scher
    Scher
  6. Chou
    Chou
  7. Moore
    Moore
  8. Motzer
    Motzer
  9. Saltz
    Saltz
  10. Bertino
    Bertino

Groups

  1. Department of Medicine (310)
  2. Sloan Kettering Institute Faculty (189)
  3. GSK Faculty (179)
  4. Solid Tumor Oncology Division (177)
  5. Molecular Pharmacology and Chemistry Program Faculty (120)
  6. Hematologic Malignancies, Division of (98)
  7. Surgery (94)
  8. Center for Hematologic Malignancies (87)
  9. Survivorship Research (82)
  10. Tow Center for Developmental Oncology (TCDO) (76)
  1. "drug effect"
Formats
  1. Journal Article (810)
  2. Conference Paper (23)
  3. Editorial (7)
  4. Review (7)
  5. Research Letter (3)
  6. Book Section (1)
  7. Guidelines (1)
Groups
  1. Department of Medicine (310)
  2. Sloan Kettering Institute Faculty (189)
  3. GSK Faculty (179)
  4. Solid Tumor Oncology Division (177)
  5. Molecular Pharmacology and Chemistry Program Faculty (120)
  6. Hematologic Malignancies, Division of (98)

More Groups

People
  1. Gavril Pasternak (27)
  2. Gary Schwartz (21)
  3. Ting-Chao Chou (21)
  4. Paul Marks (20)
  5. Howard Scher (17)
  6. Neal Rosen (17)

More People

Years
  1. 2024 (1)
  2. 2023 (10)
  3. 2022 (13)
  4. 2021 (10)
  5. 2020 (19)
  6. 2019 (8)

More Years

Publications
  1. Journal of Clinical Oncology (43)
  2. Clinical Cancer Research (32)
  3. Blood (24)
  4. Cancer Research (22)
  5. Proceedings of the National Academy of Sciences of the United States of America (17)
  6. New England Journal of Medicine (13)

More Publications

Publishers
  1. American Association for Cancer Research (79)
  2. Elsevier Inc. (65)
  3. Nature Publishing Group (52)
  4. Springer (45)
  5. American Society of Clinical Oncology (44)
  6. Elsevier Science, Inc. (38)

More Publishers

Results (852)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase II study of guadecitabine combined with irinotecan vs regorafenib or TAS-102 in irinotecan-refractory metastatic colorectal cancer patients
    Journal Article

    Lee, V.; Parkinson, R.; Zahurak, M.; Cope, L.; Cercek, A.; Verheul, H.; Gootjes, E.; Lenz, H. J.; Iqbal, S.; Jones, P.; more...
    International Journal of Cancer (2024)

    Fulltext@MSK | Save
  • E7820, an anti-cancer sulfonamide, degrades RBM39 in patients with splicing factor mutant myeloid malignancies: A phase II clinical trial
    Research Letter

    Bewersdorf, J. P.; Stahl, M.; Taylor, J.; Mi, X.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Lu, S. X.; Bourcier, J.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • ILUSTRO: Phase II multicohort trial of zolbetuximab in patients with advanced or metastatic claudin 18.2–positive gastric or gastroesophageal junction adenocarcinoma
    Journal Article

    Klempner, S. J.; Lee, K. W.; Shitara, K.; Metges, J. P.; Lonardi, S.; Ilson, D. H.; Fazio, N.; Kim, T. Y.; Bai, L. Y.; Moran, D.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Osimertinib and selpercatinib efficacy, safety, and resistance in a multicenter, prospectively treated cohort of EGFR-mutant and RET fusion-positive lung cancers
    Journal Article

    Rotow, J.; Patel, J. D.; Hanley, M. P.; Yu, H.; Awad, M.; Goldman, J. W.; Nechushtan, H.; Scheffler, M.; Kuo, C. H. S.; Rajappa, S.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • Time to progression of disease and outcomes with second-line BTK inhibitors in relapsed/refractory mantle cell lymphoma
    Journal Article

    Villa, D.; Jiang, A.; Visco, C.; Crosbie, N.; McCulloch, R.; Buege, M. J.; Kumar, A.; Bond, D. A.; Paludo, J.; Maurer, M. J.; more...
    Blood Advances (2023)

    Fulltext@MSK | Save
  • Report of consensus panel 7 from the 11th International Workshop on Waldenström Macroglobulinemia on priorities for novel clinical trials
    Conference Paper

    Tam, C. S.; Kapoor, P.; Castillo, J. J.; Buske, C.; Ansell, S. M.; Branagan, A. R.; Kimby, E.; Li, Y.; Palomba, M. L.; Qiu, L.; more...
    W.B. Saunders Co-Elsevier Inc. (2023)

    Fulltext@MSK | Save
  • Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial
    Journal Article

    Réa, D.; Boquimpani, C.; Mauro, M. J.; Minami, Y.; Allepuz, A.; Maheshwari, V. K.; D’Alessio, D.; Wu, Y.; Lawrance, R.; Narbutas, S.; more...
    Leukemia (2023)

    Fulltext@MSK | Save
  • Piperacillin-tazobactam compared with cefoxitin as antimicrobial prophylaxis for pancreatoduodenectomy: A randomized clinical trial
    Journal Article

    D'Angelica, M. I.; Ellis, R. J.; Liu, J. B.; Brajcich, B. C.; Gönen, M.; Thompson, V. M.; Cohen, M. E.; Seo, S. K.; Zabor, E. C.; Babicky, M. L.; more...
    JAMA - Journal of the American Medical Association (2023)

    Fulltext@MSK | Save
  • The herbal medicine Suanzaoren (Ziziphi Spinosae Semen) for sleep quality improvements: A systematic review and meta-analysis
    Review

    Yang, M.; Wang, H.; Zhang, Y. L.; Zhang, F.; Li, X.; Kim, S. D.; Chen, Y.; Chen, J.; Chimonas, S.; Korenstein, D.; more...
    Integrative Cancer Therapies (2023)

    Fulltext@MSK | Save
  • Effect of jianpi bushen formula for colon cancer patients who underwent adjuvant chemotherapy: Statistical analysis plan for a multicenter trial
    Journal Article

    Zhao, R.; Cao, H.; Sun, L.; Zhang, T.; Xu, Y.; Yan, S.; Mao, J.; Liu, J.; Fei, Y.; Yang, Y.
    Journal of Traditional Chinese Medical Sciences (2023)

    Fulltext@MSK | Save